Prognosis of patients with axillary lymph node metastases from occult breast cancer: analysis of multicenter dataopen access
- Authors
- Kim, Haeyoung; Park, Won; Kim, Su Ssan; Ahn, Sung Ja; Kim, Yong Bae; Kim, Tae Hyun; Kim, Jin Hee; Choi, Jin-Hwa; Park, Hae Jin; Chang, Jee Suk; Choi, Doo Ho
- Issue Date
- Jun-2021
- Publisher
- 대한방사선종양학회
- Keywords
- Unknown primary neoplasms; Breast neoplasm; Lymph nodes; Radiotherapy
- Citation
- Radiation oncology journal, v.39, no.2, pp.107 - 112
- Indexed
- SCOPUS
KCI
OTHER
- Journal Title
- Radiation oncology journal
- Volume
- 39
- Number
- 2
- Start Page
- 107
- End Page
- 112
- URI
- https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/141725
- DOI
- 10.3857/roj.2021.00241
- ISSN
- 2234-1900
- Abstract
- Purpose: This study was conducted to evaluate prognosis of patients with level I/II axillary lymph node metastases from occult breast cancer (OBC).
Materials and Methods: Data of 53 patients with OBC who received axillary lymph node dissection (ALND) positive/negative (+/–) breast-conserving surgery between 2001 and 2013 were retrospectively collected at seven hospitals in Korea. The median number of positive lymph nodes (+LNs) was 2. Seventeen patients (32.1%) had >3 +LNs. A total of 48 patients (90.6%) received radiotherapy. Extents of radiotherapy were as follows: whole-breast (WB; n = 11), regional lymph node (RLN; n = 2), and WB plus RLN (n = 35).
Results: The median follow-up time was 85 months. Recurrence was found in four patients: two in the breast, one in RLN, and one in the breast and RLN. The 5-year and 7-year disease-free survival (DFS) rates were 96.1% and 93.5%, respectively. Molecular subtype and receipt of breast radiotherapy were significantly associated with DFS. Patients with estrogen receptor negative, progesterone receptor negative, and human epidermal growth factor receptor 2 negative (ER-/PR-/HER2-) subtype had significantly lower 7-year DFS than those with non-ER-/PR-/HER2- tumor (76.9% vs. 100.0%; p = 0.03). Whole breast irradiation (WBI) was significantly associated with a higher 7-year DFS rate (94.7% for WBI group vs. 83.3% for non-WBI group; p = 0.01). Other factors including patient’s age, number of +LNs, taxane chemotherapy, and RLN irradiation were not associated with DFS.
Conclusion: Patients with OBC achieved favorable outcome after ALND and breast-targeting treatment. Molecular subtype and receipt of WBI was significant factors for DFS.
- Files in This Item
-
- Appears in
Collections - 서울 의과대학 > 서울 방사선종양학교실 > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/141725)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.